Journal of Medicinal Chemistry · 1999 · 113 citations · 18 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsLigand BindingLigand-based DesignPotency OptimizationReceptor PharmacologySelectivity DesignStructure-activity Relationship AnalysisAdrenergic AntagonistsAdrenergic Receptor AgonistsAdrenergic Receptor AntagonistsAlpha-1 Adrenergic BlockadeAlpha-adrenergic AgonistsAlpha-adrenergic Receptor PharmacodynamicsBlood PressureSubtype Discovery
Dihydropyrimidinones such as compound 12 exhibited high binding affinity and subtype selectivity for the cloned human alpha(1a) receptor. Systematic modifications of 12 led to identification of highly potent and subtype-selective compounds such as (+)-30 and (+)-103, with high binding affinity (K(i) = 0.2 nM) for alpha(1a) receptor and greater than 1500-fold selectivity over alpha(1b) and alpha(1d) adrenoceptors. The compounds were found to be functional antagonists in human, rat, and dog prostate tissues. Compound (+)-103 exhibited excellent selectively to inhibit intraurethral pressure (IUP) as compared to lowering diastolic blood pressure (DBP) in mongrel dogs (K(b)(DBP)/K(b)(IUP) = 40) suggesting uroselectivity for alpha(1a)-selective compounds.
18
High prevalence of benign prostatic hypertrophy in the community
W M Garraway, R.J. Lee, G.N. Collins · The Lancet · 1991 · 772 citations